Summary
Mahmoud Ghandi is a computational biology leader and founder with over a decade of experience building integrative genomics and AI/ML solutions for cancer research and drug discovery. He led the computational biology group for the Broad Institute’s CCLE/DepMap effort—curating and analyzing multi-omics and large-scale perturbation datasets across 1000+ cell lines—to discover vulnerabilities, biomarkers, and mechanisms of drug resistance. As Founder & CEO of Cambridge Data Science and a consultant to venture-backed biotech, he translates complex omics into predictive models and target hypotheses that de-risk therapeutic programs. Trained as a biomedical engineer with a Johns Hopkins PhD, he combines deep methodological expertise in NGS, proteomics, metabolomics and perturbation screens with hands-on experimental design experience. Notably, he has repeatedly bridged academia, industry and startups, shaping both public resources and private translational pipelines.
10 years of coding experience
6 years of employment as a software developer
Ph.D. Biomedical Engineering, Ph.D. Biomedical Engineering at The Johns Hopkins University School of Medicine
Master of Science - MS Biomedical Engineering, Master of Science - MS Biomedical Engineering at Sharif University of Technology